FDA 483 - Ipca Laboratories Limited - August 23, 2019

An FDA inspection at Ipca Laboratories Limited in Silvasa, India, from August 19-23, 2019, revealed significant deviations from current Good Manufacturing Practices (cGMP). The inspection highlighted an ineffective Quality Unit and systemic data integrity failures.

Key issues observed include uninvestigated unknown peaks in residual solvent testing, with analysts using "inhibit integration" to avoid them. The Quality Unit also demonstrated inadequate oversight, failing to detect long-standing deviations from standard test procedures by QC analysts in dissolution, assay, and related substance tests, some persisting for over 12 years.

Furthermore, the company's electronic data assessment was incomplete, as FDA investigators demonstrated the ability to retrieve and review "incomplete data" that the firm's QA personnel were unaware of. Investigations into out-of-specification (OOS) and out-of-trend (OOT) results were deficient, often invalidated without identifying root causes, and included instances where product complaints for "lack of effectiveness" were not linked to commercially sold OOT batches.

The Quality Unit also failed to adhere to timelines for product complaint investigations, with some remaining open for over a year. Critically, there were no established timelines for Change Control or Corrective and Preventive Action (CAPA) closures, leading to many remaining open for hundreds of days. Data integrity was further compromised by the destruction of interim investigation reports and the presence of uncontrolled, modifiable GMP documents on shared drives, along with unsecured raw production data on equipment interfaces.

Ipca Laboratories Limited must implement robust corrective actions to enhance Quality Unit effectiveness, ensure data integrity, validate analytical methods, improve investigation processes, and establish timely closure mechanisms for complaints, change controls, and CAPAs to comply with regulatory standards.